Can 0.01% atropine sulfate eye drops (EIKANCE) effectively control myopia?
0.01% atropine sulfate eye drops (EIKANCE) is a drug widely used to control the progression of myopia. Its mechanism of action is mainly to gently relax the ciliary muscles of the eyes, inhibit the growth of the eyeballs, and thereby slow down the progression of myopia. Unlike traditional myopia correction methods (such as glasses or contact lenses), 0.01% atropine sulfate directly affects the structure of the eye through pharmacological effects, fundamentally slowing down the progression of myopia.
Clinical studies have shown that 0.01% atropine sulfate has a significant effect in controlling myopia. Especially in children and adolescents, myopia often worsens with age, and this drug effectively controls the progression of myopia by slowing down the growth of the axial length of the eye. This treatment method can not only help children slow down the progression of myopia, but also avoid or delay other eye problems caused by myopia, such as retinal detachment and glaucoma.
Compared with conventional concentration atropine eye drops, low-concentration 0.01% atropine sulfate has less side effects. The high concentration of traditional atropine eye drops may cause side effects such as pupil dilation and light sensitivity, while the low concentration of 0.01% atropine sulfate can effectively reduce these adverse reactions, making it an ideal choice for long-term use. In addition, research also shows that 0.01% atropine sulfate has a relatively stable effect on controlling myopia during clinical use, especially in children whose myopia progresses rapidly.
Although 0.01% atropine sulfate has significant effects, parents and doctors still need to evaluate their child's specific situation. Some children may have effective control of myopia progression after using this drug, while others may not have an obvious effect. Therefore, it is still important to have regular eye exams while using this medication to ensure the continued effects of the medication.
Reference: https://www.eikance.com.au/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)